The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Yuki MatsubaraKazuhiro ToriyamaShigenori KadowakiTakatsugu OgataTaiko NakazawaKyoko KatoKazuki NozawaYukiya NaritaKazunori HondaToshiki MasuishiHideaki BandoMasashi AndoMasahiro TajikaIsao OzeWaki HosodaKei MuroPublished in: Esophagus : official journal of the Japan Esophageal Society (2023)
This study suggests that a CPS of < 1 is not a strong predictor of efficacy but can predict the absence of response to nivolumab in patients with aESCC.
Keyphrases